March 2, 2023
We are thrilled to announce a groundbreaking, first in class treatment for Geographic Atrophy –SYFOVRE™ (pegcetacoplan injection) — and incredibly proud that our own Dr. Jordana Fein was the first physician in the Washington DC area to treat patients with it yesterday!
Jordana G. Fein, M.D., M.S., Retina Specialist stated: “I am excited to be able to deliver this groundbreaking, new treatment for advanced macular degeneration to our patients. Until the approval last Friday, there were no therapeutic options for patients with geographic atrophy, which is a progressive and blinding form of macular degeneration. This is a first in class medication which reduces the rate of the progression of this disease. I was privileged to be involved in the clinical trials that led to the FDA approval of SYFOVRE™ and am hopeful that our patients will benefit from this new therapeutic option.”
Steven Madreperla, M.D., Ph.D., President and CEO of PRISM Vision Group added: “This is truly a great day. As a Retina Surgeon, I am thrilled that a treatment is now available for the many patients we take care of with geographic atrophy. As the President and CEO of PRISM Vision Group, I am incredibly proud of our clinicians to be the first in the nation to utilize this treatment as well as all those on our team that led and participated in the clinical trials that led to SYFOVRE™’s FDA approval. Our doctor’s dedication to the progression of the science of medicine through our robust clinical trials program is one of the many things that sets PRISM apart.”
To learn more about how we may be able to assist your previously untreatable patients with GA, please contact any of our offices or physicians directly, via www.rgw.com or call 844 RGW DOCS
